of the text. For the level of evidence supporting each recommendation, see Table 3 4 Level of evidence â€  In adult patients with active PsA despite treatment with an IL-17i biologic monotherapy, 1. Switch to a TNFi biologic over switching to an IL-12/23i biologic Conditional recommendation based on very-low-quality-evidence; may consider switching to IL-12/23i if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent